| Active substance | Belumosudil |
| Holder | Sanofi |
| Status | Running |
| Indication | treatment of adults with chronic Graft Versus Host Disease (cGVHD) when other treatment options provide limited clinical benefit, are not suitable, or have been exhausted |
| Public documents | |
| Last update | 17/09/2026 |